AUTHOR=Yu Mengxue , Qian Kaiyu , Wang Gang , Xiao Yu , Zhu Yuan , Ju Lingao 

TITLE=Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma

JOURNAL=Frontiers in Oncology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1114461

DOI=10.3389/fonc.2023.1114461

ISSN=2234-943X

ABSTRACT=<p>SET domain-containing 2 (SETD2) is a lysine methyltransferase that catalyzes histone H3 lysine36 trimethylation (H3K36me3) and has been revealed to play important roles in the regulation of transcriptional elongation, RNA splicing, and DNA damage repair. <italic>SETD2</italic> mutations have been documented in several cancers, including clear cell renal cell carcinoma (ccRCC). <italic>SETD2</italic> deficiency is associated with cancer occurrence and progression by regulating autophagy flux, general metabolic activity, and replication fork speed. Therefore, SETD2 is considered a potential epigenetic therapeutic target and is the subject of ongoing research on cancer-related diagnosis and treatment. This review presents an overview of the molecular functions of SETD2 in H3K36me3 regulation and its relationship with ccRCC, providing a theoretical basis for subsequent antitumor therapy based on SETD2 or H3K36me3 targets.</p>